Actualités

Minneapolis, Minnesota June 10, 2013 - At the 61st ASMS conference, Bruker introduces exciting new High-Definition capabilities in proteomics and biomarker research. Patented low-noise Captivespray nanoBooster™ ionization coupled with record high-speed digitization Qq-TOF technology and steered by intelligent acquisition software defines complex samples more sharply than ever before.
 
The novel High-Definition accurate mass spectrometer, impact HD™ is the latest innovation in Bruker’s UHR-TOF product line. It opens up enhanced analytical performance levels for all applications where trace analysis from complex, high-background matrices is challenge – such as biomarker research, identification of impurities or residue screening.  Thanks to extreme sensitivity broad mass-transfer ion optics and fastest ever 50Gbit/sec sampling technology a dynamic range of 5 orders of magnitude is achieved in one second of LC time.  Wide dynamic range at high speed is a prerequisite for high-resolution detection of low-abundance compounds in sharp UHPLC peaks and permits direct quantitation without re-run.

The HD performance is directed by unique intelligent self-optimizing Instant Expertise™ software.  MSMS acquisition parameters are dynamically adapted precisely to the incident sample, independent of sample amount or complexity, translating directly into higher productivity and expert-caliber results first time.
 
Bruker also introduces the CaptiveSpray nanoBooster™ which complements all Bruker LCMS instruments for new performance levels in proteomics and glycoanalysis. The new version of Bruker’s established CaptiveSpray source employs a novel dopant-enriched gas ionization environment to boost sensitivity, enhance charge state and reduce background noise to drive up protein ID rates significantly. The ability to engineer enhanced charge state is especially beneficial on Bruker’s amazon ETD ion trap in the structural analysis of glycopeptides by ETD.
 
The features ensure IMPACT HD delivers  the fastest time-to-success for customers across a broad applications portfolio ranging from small molecule identification and characterization; food, forensic and environmental screening, metabolomics, proteomics to antibody analysis.
 
 “Dynamic range really means something in your proteomics analysis when it can genuinely be delivered at UHPLC speeds” commented Carsten Baessmann Head of Applications Development “today we’re showing in a proteomics sample more than 8440 proteins at a false discovery rate (FDR) of better than 1%  are identified from a combined  2D LC separation experiment with a CaptiveSpray nanoBooster™ - impact HD system.”

Media Contact:
Vicky Lander, Bruker Daltonics
Director of Global Marketing Communications
T:+1-978-663-3660
E: vicky.lander@bdal.com

MINNEAPOLIS--(BUSINESS WIRE) -- Jun. 10, 2013 -- At the 61st ASMS Conference on Mass Spectrometry and Allied Topics, Bruker today announced mass spectrometry-based product introductions for life-science and clinical research, for biotech/pharma/CRO customers, as well as for industrial and applied markets. The new mass spectrometry systems and solutions are designed to deliver confident analyses with dramatically enhanced resolution, sensitivity and precision.

Major Bruker Innovations at ASMS 2013 include:

- Game-changing >10 million eXtreme Resolution on new solariX™ XR System

- Industry-leading 50 Gbit/sec sampling for 105 dynamic range on >40,000 Full-Sensitivity Resolution, 50 Hz MS/MS impact™ HD System

- Novel CaptiveSpray NanoBooster™ enables over 8,400 unique protein IDs in proteomics on impact™ HD UHR-QTOF System

- New EVOQ™ Elite ER LC-triple quad mass spectrometer for undistorted peptide quantification with proprietary VIP™ (vacuum-insulated probe) HESI sourceThe analytical utility of extreme performance will be presented in Bruker’s users’ symposium, breakfast workshops, and hospitality suite with emphasis on the following market/applications areas: systems biology, proteomics and metabolomics; biologics & pharmaceuticals; MALDI molecular imaging for pathology research and drug development; petroleomics, energy and industrial applications; applied markets including food, forensics and environmental analysis; as well as MALDI Biotyper-based clinical microbiology.

New Bruker products introduced at ASMS 2013 include:

SolariX™ XR:

With the scientifically acclaimed ParaCell™ as its core technology, the solariX XR FTMS (Fourier Transform Mass Spectrometry) system is redefining the way researchers approach chemical analysis by utilizing the concept of eXtreme Resolution throughout a wide variety of analytical workflows. Combining the ParaCell with advanced processing technology enables the solariX XR to provide resolving powers of greater than 650,000 in a 1 second acquisition (at m/z 400) for routine LC/MS or MALDI imaging experiments, and ultimately over 10 million resolving power for the most challenging complex mixture applications, from top-down proteomics, to petroleomics and dissolved-organic matter (DOM) analysis, to eXtreme Resolution MALDI imaging. This is a powerful advance in the state-of-the-art of mass spectrometry and provides access to previously hidden insights, and to chemical information never accessible before with mass spectrometry. For the first time, chemists can ‘read’ the specific molecular formula for detected compounds from the eXtreme Resolution mass spectrum - essentially with certainty. This concept is especially relevant for metabolomics or workflows where information about the chemical genesis of a compound is not known, quantities available are not sufficient for other analytical methods, and all high-sensitivity information must be determined from mass spectral data alone.

Dr. Charles Cheng of Pfizer’s Development Analytical division commented: "The isotopic fine structure that is easily revealed by the extreme resolution of the new solariX XR is of tremendous value for structural elucidation on unknowns. This fundamentally new ability to gain complete confidence in assignment of elemental formula perfectly complements our internal NMR activities at Pfizer. MALDI –FTMS was also surprisingly useful for small molecule analysis, enabling rapid high-throughput screening for statistically based impurity analysis at extreme resolution."

This novel eXtreme resolution platform is made easily applicable to a wide variety of applications by leveraging the Bruker portfolio of industry-leading MS analysis software solutions and ionization sources, such as CaptiveSpray for robust, high-sensitivity capillary and nano-flow applications. The solariX XR features an advanced dual-source ion funnel which allows effortless (~5s) changeover from API (ESI or APCI) to MALDI, thus enabling workflows such as MALDI imaging, automation for high-throughput screening (96–384 well targets) and top-down MALDI sequencing to supplement ETD and ECD sequencing of large biomolecules. The robust ion optics design of solariX XR combined with intuitive FTMSControl software results in a user interface that allows effortless, record-breaking performance. Advanced processing and mining of information-rich data sets is performed automatically and on-the-fly using Bruker applications platforms including: new flexImaging 4.0 for MALDI imaging, ProfileAnalysis for statistical treatment of complex data sets, and DataAnalysis with SmartFormula XR for automated interpretation of isotopic fine structure for exact elemental formula determination.

Impact™ HD and CaptiveSpray™ NanoBooster™ Source:

The new Impact HD is the latest innovation in Bruker’s unique UHR-QqTOF (Ultra-High Resolution Qq-Time-Of-Flight) mass spectrometry product line with industry-leading >40,000 Full-Sensitivity Resolution (FSR). It opens up enhanced analytical performance levels for all applications where trace analysis from complex, high-background matrices is a challenge – such as biomarker research, identification of impurities or residue screening.

Thanks to its extreme sensitivity, broad mass-transfer ion optics and the fastest 50 Gbit/sec sampling technology, a dynamic range of 5 orders of magnitude is achieved at UHPLC speeds, with up to 50 Hz MS/MS capabilities. This is a prerequisite for high-resolution, accurate mass detection of low abundance compounds in nano- and UHPLC peaks.

Moreover, the Impact HD comes equipped with unique Instant Expertise™ software: intelligent self-optimizing MS/MS acquisition establishes optimal experimental conditions that are independent of sample amount or complexity. This translates into higher productivity and expert-caliber results - the first time!

In combination with the impact HD, Bruker also introduces the novel CaptiveSpray nanoBooster™ for new performance levels in proteomics and glycoanalysis. This newest version of Bruker’s highly regarded CaptiveSpray ion source with proprietary dopant-enriched ionization boosts nano-flow sensitivity, and drives up protein and peptide ID rates significantly. The emphasis of higher charge states and its sensitivity gain also provide highest ETD sensitivity with Bruker’s amaZon ETD ion trap mass spectrometer, and allow for the analysis of low-level glycopeptides that were previously not measurable.

"Highest dynamic range really is compelling for proteomics analysis when it can genuinely be delivered at UHPLC speeds," commented Dr. Carsten Bässmann, Bruker’s Head of ESI Applications Development. "At ASMS 2013, we can for this first time show the unique identification of more than 8,440 proteins at a low false discovery rate (FDR) below 1%, in a proteomics sample, using an integrated workflow combining 2D-LC separations with a CaptiveSpray nanoBooster™ source on our new impact HD system."

EVOQ™ Elite ER:

The new EVOQ Elite ER highlights the premiere of LC/MS/MS triple-quadrupole (TQ) technology from Bruker at ASMS. The new EVOQ Elite ER is the latest addition to the EVOQ family of LC-TQ systems, with an extended mass range to 2,000 m/z, for peptide quantitation or other high m/z applications.

The EVOQ LC-TQ platform features major innovations:

 - the industry’s first Vacuum-Insulated Probe (VIP™) heated electrospray ionization (HESI) source preserves and ionizes thermally fragile molecules without discrimination and with outstanding sensitivity

 - the Active Exhaust atmospheric pressure ionization source with a robust orifice vacuum interface significantly enhances quantitative robustness for difficult samples

 - flat-tuning, proprietary Interlaced Quadrupole Dual Funnel (IQ-DF™) maximizes sensitivity

 - Bruker’s patented lens-free triple-quad mass filter design enhances MRM ease and performance

 - novel PACERTM software enables exception-based data-review, a revolutionary feature that significantly reduces the error rate for quantitative analysis

All EVOQ LC-TQ systems incorporate Bruker’s new Advance™ Ultra-High Pressure Liquid Chromatography (UHPLC) systems. The Advance HPLC, UHPLC, and the UHPLC-OLE (on-line extraction) products offer ultra-low dead volume, which enables excellent reproducibility at analytical flow-rates, an integrated column-oven, and bench-space savings. Paired with the industry-leading CTC auto-sampler, the EVOQ LC-TQ delivers the precision and accuracy required for sustained, high-sensitivity LC-MRM quantitative analysis.

Rohan Thakur, Ph.D., Vice President and General Manager of Bruker’s Quadrupole MS Business, stated: "The debut of the EVOQ LC-TQ at ASMS marks the first time that Bruker has brought LC triple quad technology to the premiere meeting for mass spectrometry. The key innovations in the EVOQ systems are designed to erase the pain points in today’s high volume applied markets laboratories. Laboratories supporting food testing (pesticide residues or adulterants), environmental labs (industrial pollutants or personal care products), or toxicology (drug testing/doping, pain management) will benefit from the superior performance of the EVOQ family. Bruker’s commitment to driving Innovation with Integrity is not just a tagline, it is our core philosophy."

Please join Bruker at its ASMS booth #110, and at Bruker’s ASMS press conference on Monday, June 10th, 2013 at 9:30 am to 10:30 am CDT at the Minneapolis Hilton Hotel, Conrad Room D (breakfast served, by registration only).

ABOUT BRUKER CORPORATION (NASDAQ: BRKR)

Bruker is a leading provider of high-performance scientific instruments and solutions for molecular and materials research, as well as for industrial, diagnostics and applied analysis. For more information: www.bruker.com

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20130610005097/en/

Bruker Daltonics
Vicky Lander
Director of Global Marketing Communications
+1-978-663-3660
vicky.lander@bdal.com

The MRC-NIHR Phenome Centre will examine around one hundred thousand blood and urine samples every year. It will analyse phenomes - the biological results of people's genes and environment - to help determine the causes of disease and indicate how treatments can be tailored for individual patients.

The centre will enable scientists to better understand and tackle diseases that are triggered by environment as well as genetic causes, and increase the potential to develop strategies for their prevention and treatment.

Ongoing genomics research is helping scientists to understand why some people develop diseases, but most common diseases are influenced by both genetic and environmental factors, such as diet and lifestyle. Studying the phenome will help determine how the environment and genes combine to affect biochemical processes that lead to disease.

The new centre, a collaboration between Imperial College London, King's College London, and analytical technology companies the Waters Corporation and Bruker Biospin, is funded by the Medical Research Council (MRC) and the National Institute for Health Research (NIHR). It is based at Imperial where its director is Professor Jeremy Nicholson, head of the Department of Surgery and Cancer.

Professor Nicholson said: "The sequencing of the human genome generated a lot of excitement among scientists and the public, but studying our genes has revealed less than we had hoped about common diseases such as cancer, diabetes and heart disease. By studying the phenome we can examine the effects of our genes, our lifestyle and our environment. What we discover about the causes of disease can be used to inform healthcare."

The MRC-NIHR Phenome Centre uses millions of pounds worth of nuclear magnetic resonance and mass spectrometry technology to give the most accurate readings to date of the exact chemical make-up of people's blood and urine. The equipment measures the chemicals, such as fats, sugars, vitamins and hormones, produced by our bodies as well as those that come from our food, drink and medicines, and the air we breathe. It can even detect the different types of bacteria naturally occurring in the gut, which can influence our health.

The new centre will provide a service to researchers throughout the UK, offering fast, efficient and high-quality analysis of people's phenomes.

"This technology is already in use in medical research but only on a small-scale. With the creation of this new facility, it will now be possible to get a complete and accurate biological read-out of thousands of individuals," said Professor Frank Kelly, Co-Investigator at the Centre and Director of Analytical and Environmental Sciences Division at King's College London.

"The ability to study the phenome on an industrial scale means we can pick apart the complex circumstances, genetic and environmental, that cause conditions like cancer, diabetes and heart disease."

Professor Paul Elliott, Co-Investigator at the Centre and Head of the Department of Epidemiology and Biostatistics at Imperial, said: "The MRC-NIHR Phenome Centre offers an unprecedented opportunity to apply nuclear magnetic resonance and mass spectrometry on a large scale to unlock information on genes, environment and lifestyle contained in stored blood and urine samples from thousands of people whose long-term health is being monitored."

Professor Nicholson added: "It will also allow us to see how individual patients respond to different treatments over time. For example, we could quickly discern whether a cancer patient is responding to chemotherapy and if not, switch to a different treatment, without wasting valuable time. And the data we gather will mean that, ultimately, we will be able to predict which treatments will work for which patients, based on their phenome."

One of the first projects to benefit from the technology is a study of blood pressure, a major risk factor for heart disease. The GRAPHIC study, led by Professor Nilesh Samani of the University of Leicester, was set up to investigate the genetics of high blood pressure. Blood and urine samples which have already been taken from 2,000 volunteers will now be tested at the MRC-NIHR Phenome Centre.

Professor Samani will work with staff from the centre to examine the types and levels of chemicals present in the samples. This can then be compared with existing data on the volunteers' blood pressure, their genetic make-up and information about their lifestyles. By discovering which chemicals relate to higher or lower blood pressure, researchers hope to gain the best understanding yet of this complex condition.

"We are very excited by this project. We already know that high blood pressure is partly caused by genes and partly by lifestyle and environmental factors, but we really don't understand how these interact at the protein and molecular level to raise blood pressure. This research will identify key changes in the phenome that correlate with blood pressure and help to identify mechanisms that we can target to develop better treatments," said Professor Samani, British Heart Foundation Professor of Cardiology at the University of Leicester and Director of the NIHR Leicester Cardiovascular Biomedical Research Unit.

The centre has secured funding of £10 million from the MRC and NIHR for its first five years.

Chief Medical Officer, Professor Dame Sally C Davies said: "The unprecedented capacity of the centre will allow health researchers a brand new window into how our genes interact with the environment, catalysing advances in diagnosis, treatment and personalised healthcare. This globally unique facility will also facilitate collaborative research with the life sciences industry and therefore has the potential to contribute to the nation's growth. It's a win-win situation for us all."

During its first five years, the centre will also test the thousands of samples already stored by researchers working at the NIHR's Biomedical Research Centres and Units.  The Centres and Units are collaborations between leading NHS hospitals and universities that focus on ensuring that patients benefit from the most promising medical research.

Professor Sir John Savill FRS, MRC Chief Executive said: "The UK has an extremely strong life sciences capability and world-class expertise in this area of research which applies the latest techniques in measuring the chemistry of the human body to valuable patient and subject cohort groups. The MRC-NIHR Phenome Centre is a superb national resource in a strong partnership with industry, unlocking a great deal of potential in UK bioscience and will ultimately result in huge benefits for patients."

Thanks to donations of additional equipment from Waters and Bruker, the centre will also include a state-of-the-art international training facility. This will enable students, scientists and doctors from around the world to gain hands-on experience of using analytical technology to study the human phenome.

Art Caputo, President of the Waters Division at Waters Corporation, said: "Waters is proud to be part of this first-of-a-kind research centre and the opportunity to work with such distinguished partners. Our mission at Waters is to advance science to constantly push the boundaries of what's possible. We fully expect this centre will do just that, multiplying our understanding of disease, setting the standard for this field of research and continually helping us to improve the health of populations around the world. There are no limits to the breakthroughs in health we might see as a result of work here at the NIHR-MRC Phenome Centre and hopefully in the near future in affiliated centres across the world, too."

Dr Manfred Spraul, Director of Applied NMR Business Development at Bruker BioSpin GmbH, said: "We are pleased that Bruker's cutting-edge NMR solutions can provide the fully automatic analysis capabilities required to help drive the centre's huge screening programme. Establishing a high throughput system was the first step in bringing NMR inside a healthcare environment, providing large scale epidemiology screening at the same time. Now we are very excited to see our technology impacting the wider field, enabling the personalised phenotyping that will help provide ever more accurate diagnoses and drive new drug development and targeted treatment."

- Ends -

Metabolic Profiler

For further information contact:

Kerry Noble
Research Editor and News Manager
Imperial College London
Email: k.noble@imperial.ac.uk
Tel: +44 (0)7446 869 433
Out of hours duty press officer: +44(0)7803 886 248

or

Simon Levey
Research Media Officer
Imperial College London
Email: s.levey@imperial.ac.uk
Tel: +44 (0)20 7594 6702

BREMEN, Germany--(BUSINESS WIRE)--Jun. 4, 2013-- Bruker Corporation today announced that it has signed an exclusive patent license agreement with 3M Company, which allows Bruker to include 3M patented innovations relating to matrix-assisted laser desorption ionization (MALDI) mass spectrometry imaging.

The licensed 3M patents are directed to a technique for performing mass spectrometry analysis on proteins in tissue that has been preserved in paraffin. The technology enables researchers to more easily study formalin-fixed, paraffin-embedded (FFPE) tissue for life-science research and drug development.

MALDI imaging has been increasingly used to analyze clinically relevant tissues such as tumor biopsies. The molecular phenotypes observed by MALDI imaging have been shown to correlate with parameters such as disease status or patient outcome, and have been successfully applied to the classification of tissue samples.

MALDI imaging was originally developed for the analysis of fresh, frozen tissue sections, but the analysis of preserved FFPE tissue sections is becoming increasingly important due to methodological improvements. In the MALDI imaging community it is widely accepted that a meaningful analysis of FFPE tissue requires a pretreatment called antigen-retrieval.

Dr. Sören-Oliver Deininger, Market Manager for MALDI imaging at Bruker, stated: “The interest in the analysis of FFPE tissue by MALDI imaging is increasing strongly. Bruker has developed innovative technology to make MALDI imaging viable in histopathology by the integration of virtual microscopy and the possibility to classify tissue based on the molecular phenotypes (class-imaging). Our license agreement with 3M shows our ongoing commitment to the MALDI imaging field, and gives our customers the necessary freedom to conduct their research and advance the field.”

“We are pleased to license these patents to Bruker, a leader in the field of MALDI imaging, and see this technology applied in the market,” said Dr. Todd Fruchterman, Senior Vice President of Research & Development and Chief Medical Officer for 3M Health Care. “We hope that this license agreement will accelerate the research in MALDI imaging of FFPE tissue, and enable it to ultimately become a valuable diagnostic tool.”

Dr. Hartmut Schlüter, Professor at the University Medical Center Hamburg-Eppendorf, has recently published a MALDI imaging study on more than 1,000 FFPE prostate cancer samples using Bruker’s MALDI Molecular Imager solution. He explained: “FFPE tissue is particularly important for the analysis by MALDI imaging because of the large available archives of such tissue with patient follow-up data and the possibility to use tissue microarrays for the analysis. Furthermore, FFPE tissue is the standard for histopathological diagnosis. Any future diagnostic application of MALDI imaging will likely need to be established on FFPE tissue.”

Note: Bruker MALDI imaging systems and solutions are for research use only (RUO).

ABOUT 3M COMPANY (NYSE: MMM)
3M captures the spark of new ideas and transforms them into thousands of ingenious products. Our culture of creative collaboration inspires a never-ending stream of powerful technologies that make life better. 3M is the innovation company that never stops inventing. With $30 billion in sales, 3M employs about 88,000 people worldwide and has operations in more than 70 countries. For more information, visit www.3M.com or follow @3MNews on Twitter.

ABOUT BRUKER CORPORATION (NASDAQ: BRKR)
Bruker is a leading provider of high-performance scientific instruments and solutions for molecular and materials research, as well as for industrial, diagnostics and applied analysis.
For more information: www.bruker.com

Contact:
Bruker Daltonik GmbH
Bremen, Germany
Dr. Sören Deininger,
+49-421-2205-270
Soeren-Oliver.Deininger@bdal.de

or

Bruker Daltonics
Vicky Lander,
+1-978-663-3660
Director of Global Marketing Communications Services
vicky.lander@bdal.com

BREMEN, Germany – May 14, 2013 -  MALDI (Matrix-Assisted Laser Desorption Ionization) imaging is a mass spectrometric imaging technique that allows the untargeted measurement of proteins, peptides, lipids, drugs and metabolites directly from tissue. MALDI imaging has been successfully applied in various research fields. A particular area of application is the histopathology research concerned with the definition of molecular phenotypes in cancer, like expression patterns that are associated with progression of cancer, or the discovery of novel proteins associated with metastasis.

Technological improvements in recent years have increased the acquisition speed and spatial resolution of MALDI imaging datasets, generating demand for software that can handle the massive amount of data and helps in the generation of biological knowledge.

SCiLS Lab is the software developed by SCiLS GmbH which allows the user-friendly statistical analysis of large MALDI imaging datasets. It features new concepts such as an edge-preserving spatial de-noising and spatial segmentation of datasets with virtually un-limited size. It also allows the comprehensive analysis of studies with many patients, including unsupervised clustering and supervised classification.

“Comprehensive statistical analysis of large MALDI imaging datasets is one of the major demands of our customers”, said Dr. Shannon Cornett, Applications Development Manager and expert for MALDI imaging at Bruker. “The SCiLS team has channeled their mathematical and statistical expertise into a software product that surpasses anything that is currently available on the market. It integrates perfectly with our own flexImaging™ software and will be an integral part of our complete MALDI imaging solution. Unquestionably, SCiLS Lab will set new standards for analyzing MALDI imaging data, and I am confident that our customers will see tremendous benefit from this exclusive collaboration as it improves their imaging workflow.”

Dr. Dennis Trede, Managing Director at SCiLS GmbH, added: “We are happy to collaborate with the market and technology leader in the field of MALDI imaging and to benefit from Bruker’s distribution channels. We believe our software can push MALDI imaging forward by enabling the analysis of large data sets with unprecedented ease of use for everyone.”

Dr. Ferdinand von Eggeling, Professor at the University Hospital in Jena, Germany and user of Bruker’s MALDI imaging equipment explains: “We use MALDI imaging for the molecular analysis of head and neck cancers. My lab has been beta-testing the SCiLS Lab software, and the SCiLS team has been very knowledgeable and responsive to our suggestions. This software will enable the analysis of complex tumor tissues and make results more descriptive and accessible. ”
 
About SCiLS
SCiLS GmbH is an R&D company located in Bremen, Germany. SCiLS develops and markets the SCiLS Lab software for analysis and interpretation of MALDI imaging mass spectrometry data. SCiLS GmbH closely cooperates with the Steinbeis Innovation Center "SCiLS Research", and SCiLS is carrying out research projects on the European level contributing with R&D innovations and serving as a core platform for 2D and 3D MALDI-imaging data. For more information, please visit www.scils.de.

About Bruker Corporation
Bruker Corporation (NASDAQ: BRKR) is a leading provider of high performance scientific instruments and solutions for molecular and materials research, as well as industrial, diagnostics and applied analysis. For more information, please visit www.bruker.com.

For Further Information:
Dr. Sören-Oliver Deininger
Bruker Daltonik GmbH, Bremen, Germany
T: +49-421-2205-403
E:  sod(at)bdal.de

Media Contact:
Vicky Lander
Director of Global Marketing Communications Services
T: +1-978-663-3660
E: vicky.lander(at)bdal.com